Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney disease
Not Applicable
Recruiting
- Conditions
- Renal anemia in chronic kidney disease
- Registration Number
- JPRN-UMIN000009472
- Lead Sponsor
- Fukuoka Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients on hemodialysis or peritoneal dialysis (2)Patients who underwent renal transplant (3)Patients with malignancy or hematological diseases (such as MDS) (4)Patients with severe complications, such as severe infections (5)Patients who take iron therapy (6)Patients who are judged to be ineligible by an attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)Comparison of changes in hepcidin concentrations between patients treated with rHuEPO or those treated with epoetin beta pegol (2)Identification of factors affecting the treatment response to rHuEPO or epoetin beta pegol
- Secondary Outcome Measures
Name Time Method (1)Effects of rHuEPO and epoetin beta pegol on iron metabolism (2)Changes in dosage of epoetin beta pegol and Hb level